Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation

This publication has 16 references indexed in Scilit:

• PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism
  Nature Communications, 2019
• EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma
  Neuro-Oncology, 2019
• Transcriptomic and epigenetic profiling of ‘diffuse midline gliomas, H3 K27M-mutant’ discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location
  Acta Neuropathologica Communications, 2018
• Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas
  Acta Neuropathologica, 2018
• Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial
  Cancer Cell, 2018
• DNA methylation-based classification of central nervous system tumours
  Nature, 2018
• Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome
  Acta Neuropathologica, 2017
• The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
  Acta Neuropathologica, 2016
• Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity
  Acta Neuropathologica, 2015
• Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes
  Acta Neuropathologica, 2015